|
FY2026
12 months to Mar 31, 2026
|
FY2025
12 months to Mar 31, 2025
|
FY2024
12 months to Mar 31, 2024
|
FY2023
12 months to Mar 31, 2023
|
FY2022
12 months to Mar 31, 2022
|
|
|---|---|---|---|---|---|
| NET REVENUE | |||||
| Cost of Sales | |||||
| Gross Profit | |||||
| Operating Expenses: | |||||
| Sales and Marketing | |||||
| Research and Development | |||||
| General and Administrative | |||||
| Impairment Expense | |||||
| Total Operating Expenses | |||||
| Operating Loss | |||||
| Other Income (Expense) | |||||
| Loss on Disposal of Assets | |||||
| Gain on Extinguishment of debt | |||||
| Settlement Expense | |||||
| Unrealized Loss on Change in Derivative Liabilities | |||||
| Other Income | |||||
| Interest Income | |||||
| Interest Expense | |||||
| Total Other Income (Expense) | |||||
| Loss before taxes | |||||
| Net Loss | |||||
| Less: Series B Preferred Stock Dividends | |||||
| Net Loss Available to Common Stockholders | |||||
| Net Loss Per Share: | |||||
| Basic | |||||
| Diluted | |||||
| Weighted Average Common Shares Outstanding: | |||||
| Basic | |||||
| Diluted | |||||
Loading...